Is GoodRx Holdings, Inc. overvalued or undervalued?

As of 3 October 2025, the valuation grade for GoodRx Holdings, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key valuation ratios highlight this assessment, with a P/E ratio of 38, an EV to EBITDA of 9.64, and a Price to Book Value of 2.23, all suggesting that the stock is trading at a premium compared to its earnings and assets.
In comparison to peers, GoodRx's P/E ratio is significantly higher than that of PropertyGuru Group Ltd., which has a P/E of -132.05, and ZipRecruiter, Inc., which stands at -12.45, indicating that GoodRx is priced much higher relative to its earnings potential. Furthermore, the company's recent stock performance shows a 1-week return of 12.13%, outperforming the S&P 500's 1.09%, but over the longer term, the stock has underperformed, with a 1-year return of -34.16% compared to the S&P 500's 17.82%. This reinforces the notion that GoodRx is currently overvalued in the market.